Atlanta Consulting Group Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Atlanta Consulting Group Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,279 shares of the company's stock after purchasing an additional 3,341 shares during the quarter. Atlanta Consulting Group Advisors LLC's holdings in Johnson & Johnson were worth $2,314,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 16.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after purchasing an additional 3,139,499 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Johnson & Johnson by 10.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock valued at $2,744,979,000 after buying an additional 1,831,751 shares during the period. Ameriprise Financial Inc. lifted its holdings in Johnson & Johnson by 5.5% in the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company's stock valued at $2,100,427,000 after acquiring an additional 754,200 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Johnson & Johnson by 16.2% in the second quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the company's stock worth $1,921,565,000 after acquiring an additional 1,829,257 shares during the period. Finally, American Century Companies Inc. raised its position in Johnson & Johnson by 5.8% in the second quarter. American Century Companies Inc. now owns 8,014,213 shares of the company's stock valued at $1,171,357,000 after purchasing an additional 437,637 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.4 %

NYSE:JNJ traded up $2.13 during mid-day trading on Friday, hitting $154.00. The stock had a trading volume of 11,328,515 shares, compared to its average volume of 6,621,219. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a 50-day simple moving average of $161.35 and a two-hundred day simple moving average of $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $370.77 billion, a PE ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.66 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company's stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wolfe Research started coverage on Johnson & Johnson in a report on Friday. They set an "outperform" rating and a $190.00 price target for the company. Citigroup lifted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, October 16th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada raised their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $175.94.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.